Annual CFF
$6.27 M
+$6.49 M+2898.21%
31 December 2023
Summary:
GT Biopharma annual cash flow from financing activities is currently $6.27 million, with the most recent change of +$6.49 million (+2898.21%) on 31 December 2023. During the last 3 years, it has fallen by -$6.26 million (-49.98%). GTBP annual CFF is now -85.19% below its all-time high of $42.32 million, reached on 31 December 2021.GTBP Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$0.00
-$2.98 M-100.00%
30 September 2024
Summary:
GT Biopharma quarterly cash flow from financing activities is currently $0.00, with the most recent change of -$2.98 million (-100.00%) on 30 September 2024. Over the past year, it has stayed the same.GTBP quarterly CFF is now -100.00% below its all-time high of $25.94 million, reached on 31 March 2021.GTBP Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$2.98 M
$0.000.00%
30 September 2024
Summary:
GT Biopharma TTM cash flow from financing activities is currently $2.98 million, unchanged on 30 September 2024. Over the past year, it has dropped by -$3.29 million (-52.51%). GTBP TTM CFF is now -94.08% below its all-time high of $50.25 million, reached on 30 June 2021.GTBP TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GTBP Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2898.2% | 0.0% | -52.5% |
| 3 y3 years | -50.0% | -100.0% | -94.0% |
| 5 y5 years | -38.5% | -100.0% | -10.7% |
GTBP Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -85.2% | +2898.2% | -100.0% | +100.0% | -94.0% | +1428.6% |
| 5 y | 5 years | -85.2% | +2898.2% | -100.0% | +100.0% | -94.1% | +1428.6% |
| alltime | all time | -85.2% | +344.8% | -100.0% | +100.0% | -94.1% | +216.3% |
GT Biopharma Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $0.00(-100.0%) | $2.98 M(0.0%) |
| June 2024 | - | $2.98 M(>+9900.0%) | $2.98 M(>+9900.0%) |
| Mar 2024 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Dec 2023 | $6.27 M(-2898.2%) | $0.00(0.0%) | $6.27 M(+0.0%) |
| Sept 2023 | - | $0.00(0.0%) | $6.27 M(0.0%) |
| June 2023 | - | $0.00(-100.0%) | $6.27 M(+3.7%) |
| Mar 2023 | - | $6.27 M(<-9900.0%) | $6.04 M(-2798.2%) |
| Dec 2022 | -$224.00 K(-100.5%) | -$1000.00(<-9900.0%) | -$224.00 K(+0.4%) |
| Sept 2022 | - | $0.00(-100.0%) | -$223.00 K(+159.3%) |
| June 2022 | - | -$223.00 K(<-9900.0%) | -$86.00 K(-100.5%) |
| Mar 2022 | - | $0.00(0.0%) | $16.38 M(-61.3%) |
| Dec 2021 | $42.32 M(+237.7%) | $0.00(-100.0%) | $42.32 M(-14.0%) |
| Sept 2021 | - | $137.00 K(-99.2%) | $49.19 M(-2.1%) |
| June 2021 | - | $16.24 M(-37.4%) | $50.25 M(+31.3%) |
| Mar 2021 | - | $25.94 M(+277.4%) | $38.27 M(+205.4%) |
| Dec 2020 | $12.53 M(+265.7%) | $6.87 M(+472.8%) | $12.53 M(+113.9%) |
| Sept 2020 | - | $1.20 M(-71.8%) | $5.86 M(+4.0%) |
| June 2020 | - | $4.26 M(+2028.5%) | $5.63 M(+110.5%) |
| Mar 2020 | - | $200.00 K(0.0%) | $2.67 M(-21.9%) |
| Dec 2019 | $3.43 M(-66.4%) | $200.00 K(-79.5%) | $3.43 M(+2.9%) |
| Sept 2019 | - | $975.00 K(-25.0%) | $3.33 M(-43.8%) |
| June 2019 | - | $1.30 M(+36.6%) | $5.93 M(+28.1%) |
| Mar 2019 | - | $952.00 K(+815.4%) | $4.63 M(-54.6%) |
| Dec 2018 | $10.20 M(+70.2%) | $104.00 K(-97.1%) | $10.20 M(+1.0%) |
| Sept 2018 | - | $3.57 M(>+9900.0%) | $10.09 M(-11.9%) |
| June 2018 | - | $0.00(-100.0%) | $11.45 M(-1.7%) |
| Mar 2018 | - | $6.52 M(>+9900.0%) | $11.65 M(+94.4%) |
| Dec 2017 | $5.99 M(+215.0%) | $0.00(-100.0%) | $5.99 M(0.0%) |
| Sept 2017 | - | $4.93 M(+2428.2%) | $5.99 M(+321.0%) |
| June 2017 | - | $195.00 K(-77.5%) | $1.42 M(-45.6%) |
| Mar 2017 | - | $866.00 K(>+9900.0%) | $2.62 M(+37.6%) |
| Dec 2016 | $1.90 M(-50.6%) | $0.00(-100.0%) | $1.90 M(-33.3%) |
| Sept 2016 | - | $362.00 K(-74.0%) | $2.85 M(-6.2%) |
| June 2016 | - | $1.39 M(+826.7%) | $3.04 M(+84.2%) |
| Mar 2016 | - | $150.00 K(-84.2%) | $1.65 M(-57.1%) |
| Dec 2015 | $3.85 M(+49.1%) | $950.00 K(+72.7%) | $3.85 M(-7.3%) |
| Sept 2015 | - | $550.00 K(>+9900.0%) | $4.15 M(-14.2%) |
| June 2015 | - | $0.00(-100.0%) | $4.84 M(-0.8%) |
| Mar 2015 | - | $2.35 M(+87.4%) | $4.88 M(+89.0%) |
| Dec 2014 | $2.58 M(+507.8%) | $1.25 M(+1.1%) | $2.58 M(+47.3%) |
| Sept 2014 | - | $1.24 M(+3079.5%) | $1.75 M(+241.7%) |
| June 2014 | - | $39.00 K(-22.0%) | $513.00 K(+8.2%) |
| Mar 2014 | - | $50.00 K(-88.2%) | $474.00 K(+11.5%) |
| Dec 2013 | $425.00 K(-54.3%) | $424.00 K(>+9900.0%) | $425.00 K(+34.5%) |
| Sept 2013 | - | $0.00(0.0%) | $316.00 K(-39.6%) |
| June 2013 | - | $0.00(-100.0%) | $523.00 K(-26.4%) |
| Mar 2013 | - | $1000.00(-99.7%) | $711.00 K(-23.5%) |
| Dec 2012 | $930.00 K(-7.1%) | $315.00 K(+52.2%) | $930.00 K(-9.8%) |
| Sept 2012 | - | $207.00 K(+10.1%) | $1.03 M(+23.6%) |
| June 2012 | - | $188.00 K(-14.5%) | $834.00 K(-26.0%) |
| Mar 2012 | - | $220.00 K(-47.1%) | $1.13 M(+12.6%) |
| Dec 2011 | $1.00 M(+238.2%) | $416.00 K(+4060.0%) | $1.00 M(+19.9%) |
| Sept 2011 | - | $10.00 K(-97.9%) | $835.00 K(+1.2%) |
| June 2011 | - | $481.00 K(+411.7%) | $825.00 K(+139.8%) |
| Mar 2011 | - | $94.00 K(-62.4%) | $344.00 K(+16.2%) |
| Dec 2010 | $296.00 K(-86.6%) | $250.00 K(>+9900.0%) | $296.00 K(-85.4%) |
| Sept 2010 | - | $0.00(0.0%) | $2.02 M(0.0%) |
| June 2010 | - | $0.00(-100.0%) | $2.02 M(-9.9%) |
| Mar 2010 | - | $46.00 K(-97.7%) | $2.24 M(+1.6%) |
| Dec 2009 | $2.21 M(>+9900.0%) | $1.98 M(>+9900.0%) | $2.21 M(+847.6%) |
| Sept 2009 | - | $0.00(-100.0%) | $233.00 K(0.0%) |
| June 2009 | - | $223.00 K(+2130.0%) | $233.00 K(+2230.0%) |
| Mar 2009 | - | $10.00 K(>+9900.0%) | $10.00 K(>+9900.0%) |
| Dec 2008 | $0.00 | $0.00(0.0%) | $0.00(0.0%) |
| Sept 2008 | - | $0.00(0.0%) | $0.00(-100.0%) |
| June 2008 | - | $0.00(0.0%) | $500.00 K(0.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2008 | - | $0.00(0.0%) | $500.00 K(-119.5%) |
| Dec 2007 | -$2.56 M(-286.5%) | $0.00(-100.0%) | -$2.56 M(+37.5%) |
| Sept 2007 | - | $500.00 K(>+9900.0%) | -$1.86 M(-20.8%) |
| June 2007 | - | $0.00(-100.0%) | -$2.35 M(+2.8%) |
| Mar 2007 | - | -$3.06 M(-538.4%) | -$2.29 M(-266.6%) |
| Dec 2006 | $1.37 M(-66.5%) | $698.00 K(+5716.7%) | $1.37 M(-64.1%) |
| Sept 2006 | - | $12.00 K(-81.0%) | $3.83 M(+2.7%) |
| June 2006 | - | $63.00 K(-89.5%) | $3.73 M(+7.9%) |
| Mar 2006 | - | $600.00 K(-81.0%) | $3.45 M(-15.7%) |
| Dec 2005 | $4.09 M(-28.1%) | $3.15 M(-3679.5%) | $4.09 M(-15.9%) |
| Sept 2005 | - | -$88.00 K(-58.1%) | $4.87 M(-2.4%) |
| June 2005 | - | -$210.00 K(-116.9%) | $4.99 M(-22.4%) |
| Mar 2005 | - | $1.24 M(-68.4%) | $6.42 M(+12.8%) |
| Dec 2004 | $5.69 M(+2204.5%) | $3.93 M(>+9900.0%) | $5.69 M(+220.0%) |
| Sept 2004 | - | $30.00 K(-97.6%) | $1.78 M(-10.3%) |
| June 2004 | - | $1.23 M(+140.4%) | $1.98 M(+162.0%) |
| Mar 2004 | - | $510.00 K(+3823.1%) | $757.00 K(+206.5%) |
| Dec 2003 | $247.00 K(-82.4%) | $13.00 K(-94.4%) | $247.00 K(+8.3%) |
| Sept 2003 | - | $234.00 K(>+9900.0%) | $228.00 K(-1185.7%) |
| June 2003 | - | $0.00(0.0%) | -$21.00 K(-55.3%) |
| Mar 2003 | - | $0.00(-100.0%) | -$47.00 K(-103.3%) |
| Dec 2002 | $1.41 M(-763.2%) | -$6000.00(-60.0%) | $1.41 M(+1.7%) |
| Sept 2002 | - | -$15.00 K(-42.3%) | $1.38 M(+12.4%) |
| June 2002 | - | -$26.00 K(-101.8%) | $1.23 M(-1.4%) |
| Mar 2002 | - | $1.45 M(-4943.3%) | $1.25 M(-688.7%) |
| Dec 2001 | -$212.00 K(-103.9%) | -$30.00 K(-82.0%) | -$212.00 K(-55.3%) |
| Sept 2001 | - | -$167.00 K(+1987.5%) | -$474.00 K(+50.5%) |
| June 2001 | - | -$8000.00(+14.3%) | -$315.00 K(-129.3%) |
| Mar 2001 | - | -$7000.00(-97.6%) | $1.07 M(-80.4%) |
| Dec 2000 | $5.47 M(-469.6%) | -$292.00 K(+3550.0%) | $5.47 M(-7.0%) |
| Sept 2000 | - | -$8000.00(-100.6%) | $5.88 M(+1.6%) |
| June 2000 | - | $1.38 M(-68.5%) | $5.79 M(+31.3%) |
| Mar 2000 | - | $4.39 M(+3524.8%) | $4.41 M(-398.0%) |
| Dec 1999 | -$1.48 M(-121.8%) | $121.00 K(-221.0%) | -$1.48 M(-7.6%) |
| Sept 1999 | - | -$100.00 K(<-9900.0%) | -$1.60 M(-328.6%) |
| June 1999 | - | $0.00(-100.0%) | $700.00 K(-86.5%) |
| Mar 1999 | - | -$1.50 M(<-9900.0%) | $5.20 M(-23.5%) |
| Dec 1998 | $6.80 M(+15.3%) | $0.00(-100.0%) | $6.80 M(+3.0%) |
| Sept 1998 | - | $2.20 M(-51.1%) | $6.60 M(+50.0%) |
| June 1998 | - | $4.50 M(+4400.0%) | $4.40 M(-25.4%) |
| Mar 1998 | - | $100.00 K(-150.0%) | $5.90 M(0.0%) |
| Dec 1997 | $5.90 M(+34.1%) | -$200.00 K(<-9900.0%) | $5.90 M(-27.2%) |
| Sept 1997 | - | $0.00(-100.0%) | $8.10 M(+1.3%) |
| June 1997 | - | $6.00 M(+5900.0%) | $8.00 M(+116.2%) |
| Mar 1997 | - | $100.00 K(-95.0%) | $3.70 M(-15.9%) |
| Dec 1996 | $4.40 M(-4.3%) | $2.00 M(-2100.0%) | $4.40 M(+57.1%) |
| Sept 1996 | - | -$100.00 K(-105.9%) | $2.80 M(-39.1%) |
| June 1996 | - | $1.70 M(+112.5%) | $4.60 M(-6.1%) |
| Mar 1996 | - | $800.00 K(+100.0%) | $4.90 M(+6.5%) |
| Dec 1995 | $4.60 M(>+9900.0%) | $400.00 K(-76.5%) | $4.60 M(+7.0%) |
| Sept 1995 | - | $1.70 M(-15.0%) | $4.30 M(+72.0%) |
| June 1995 | - | $2.00 M(+300.0%) | $2.50 M(+400.0%) |
| Mar 1995 | - | $500.00 K(+400.0%) | $500.00 K(>+9900.0%) |
| Dec 1994 | $0.00(0.0%) | $100.00 K(-200.0%) | $0.00(-100.0%) |
| Sept 1994 | - | -$100.00 K(<-9900.0%) | -$100.00 K(<-9900.0%) |
| June 1994 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 1994 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 1993 | $0.00(0.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Sept 1993 | - | $0.00(0.0%) | -$300.00 K(<-9900.0%) |
| June 1993 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 1993 | - | $0.00(-100.0%) | $0.00(0.0%) |
| Dec 1992 | $0.00(0.0%) | -$300.00 K(-200.0%) | $0.00(-100.0%) |
| Sept 1992 | - | $300.00 K(>+9900.0%) | $300.00 K(>+9900.0%) |
| June 1992 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 1992 | - | $0.00 | $0.00 |
| Dec 1991 | $0.00 | - | - |
FAQ
- What is GT Biopharma annual cash flow from financing activities?
- What is the all time high annual CFF for GT Biopharma?
- What is GT Biopharma annual CFF year-on-year change?
- What is GT Biopharma quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for GT Biopharma?
- What is GT Biopharma quarterly CFF year-on-year change?
- What is GT Biopharma TTM cash flow from financing activities?
- What is the all time high TTM CFF for GT Biopharma?
- What is GT Biopharma TTM CFF year-on-year change?
What is GT Biopharma annual cash flow from financing activities?
The current annual CFF of GTBP is $6.27 M
What is the all time high annual CFF for GT Biopharma?
GT Biopharma all-time high annual cash flow from financing activities is $42.32 M
What is GT Biopharma annual CFF year-on-year change?
Over the past year, GTBP annual cash flow from financing activities has changed by +$6.49 M (+2898.21%)
What is GT Biopharma quarterly cash flow from financing activities?
The current quarterly CFF of GTBP is $0.00
What is the all time high quarterly CFF for GT Biopharma?
GT Biopharma all-time high quarterly cash flow from financing activities is $25.94 M
What is GT Biopharma quarterly CFF year-on-year change?
Over the past year, GTBP quarterly cash flow from financing activities has changed by $0.00 (0.00%)
What is GT Biopharma TTM cash flow from financing activities?
The current TTM CFF of GTBP is $2.98 M
What is the all time high TTM CFF for GT Biopharma?
GT Biopharma all-time high TTM cash flow from financing activities is $50.25 M
What is GT Biopharma TTM CFF year-on-year change?
Over the past year, GTBP TTM cash flow from financing activities has changed by -$3.29 M (-52.51%)